Premium
Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH‐RH antagonist, after subcutaneous administration in healthy premenopausal women
Author(s) -
Nagaraja Nelamangala V.,
Pechstein Birgit,
Erb Katharina,
Klipping Christine,
Hermann Robert,
Niebch Georg,
Derendorf Hartmut
Publication year - 2000
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1067/mcp.2000.111481
Subject(s) - luteinizing hormone , pharmacokinetics , endocrinology , medicine , ovulation , pharmacodynamics , follicle stimulating hormone , hormone , hormone antagonist , chemistry , pharmacology , endocrine system
Purpose The purpose of this study was the development of pharmacokinetic and pharmacodynamic models for the luteinizing hormone (LH) suppression and subsequent shift in LH surge and follicle‐stimulating hormone by cetrorelix in women. Background Cetrorelix is a potent luteinizing hormone‐releasing hormone (LH‐RH) antagonist and is used for the prevention of the premature ovulation indicated by an LH surge in in vitro fertilization. The pharmacokinetic and pharmacodynamic relationship for the suppression and the shift in the LH surge has not yet been established. Methods In a placebo‐controlled study, single subcutaneous doses of 1, 3, and 5 mg of cetrorelix were given to 36 subjects on day 8 of the natural menstrual cycle. Cetrorelix, LH, follicle‐stimulating hormone, estradiol, and progesterone were determined. Results Cetrorelix pharmacokinetics were described by a 2‐compartment model with a terminal half‐life of 56.9 ± 27.1 hours. Mean shift in LH surge was by 4.1, 7.5, and 9.3 days with the 1‐, 3‐, and 5‐mg doses, respectively. An indirect response sigmoid E max model was developed for the suppression of LH and the shift in the LH surge. The inhibitory concentration of 50% (for LH suppression) and median effective concentration (for surge shift) estimates were 3.6 ng/mL and 1.6 ng/mL, respectively. The suppression of follicle‐stimulating hormone was described by a similar E max model, with an inhibitory concentration of 50% of 7.25 ng/mL. Conclusions A pharmacokinetic and pharmacodynamic model was developed for the transient initial suppression of LH and the subsequent shift in the LH surge after 3 single subcutaneous doses of cetrorelix without ovarian stimulation. A separate model was developed for the suppression of follicle‐stimulating hormone by cetrorelix. The shift in the LH surge could be adequately described by the model. (Clin Pharmacol Ther 2000;68:617–25.) Clinical Pharmacology & Therapeutics (2000) 68 , 617–625; doi: 10.1067/mcp.2000.111481